View in EDS

Preclinical toxicity studies supporting 2DG for treatment of status epilepticus.

Saved in:
Bibliographic Details
Title: Preclinical toxicity studies supporting 2DG for treatment of status epilepticus.
Authors: Sutula TP; Department of Neurology, University of Wisconsin, Madison WI, USA; Hexokine Therapeutics, Inc. Madison WI, USA. Electronic address: sutula@neurology.wisc.edu., Fountain NB; Department of Neurology, F.E. Dreifuss Comprehensive Epilepsy Program, University of Virginia, Charlottesville VA, USA; Hexokine Therapeutics, Inc. Madison WI, USA.
Source: Epilepsy & behavior : E&B [Epilepsy Behav] 2024 Nov; Vol. 160, pp. 110004. Date of Electronic Publication: 2024 Sep 05.
Publication Type: Journal Article; Review
Journal Info: Publisher: Academic Press Country of Publication: United States NLM ID: 100892858 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1525-5069 (Electronic) Linking ISSN: 15255050 NLM ISO Abbreviation: Epilepsy Behav Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39241638
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Preclinical toxicity studies supporting 2DG for treatment of status epilepticus.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Sutula+TP%22">Sutula TP</searchLink>; Department of Neurology, University of Wisconsin, Madison WI, USA; Hexokine Therapeutics, Inc. Madison WI, USA. Electronic address: sutula@neurology.wisc.edu.<br /><searchLink fieldCode="AU" term="%22Fountain+NB%22">Fountain NB</searchLink>; Department of Neurology, F.E. Dreifuss Comprehensive Epilepsy Program, University of Virginia, Charlottesville VA, USA; Hexokine Therapeutics, Inc. Madison WI, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22100892858%22">Epilepsy & behavior : E&B</searchLink> [Epilepsy Behav] 2024 Nov; Vol. 160, pp. 110004. <i>Date of Electronic Publication: </i>2024 Sep 05.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Review
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Academic+Press%22">Academic Press </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>100892858 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1525-5069 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215255050%22">15255050 </searchLink><i>NLM ISO Abbreviation: </i>Epilepsy Behav <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39241638
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.yebeh.2024.110004
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 110004
    Titles:
      – TitleFull: Preclinical toxicity studies supporting 2DG for treatment of status epilepticus.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Sutula TP
      – PersonEntity:
          Name:
            NameFull: Fountain NB
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 11
              Text: 2024 Nov
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1525-5069
          Numbering:
            – Type: volume
              Value: 160
          Titles:
            – TitleFull: Epilepsy & behavior : E&B
              Type: main
ResultId 1